These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 8574929)

  • 41. Meropenem: a new carbapenem antimicrobial.
    Pryka RD; Haig GM
    Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1990; 13(1):57-61. PubMed ID: 2331851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
    Rhomberg PR; Jones RN;
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):365-72. PubMed ID: 12967752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.
    Neu HC; Chin NX; Saha G; Labthavikul P
    Antimicrob Agents Chemother; 1986 Dec; 30(6):828-34. PubMed ID: 3545068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Meropenem: microbiologic perspective].
    García-Rodríguez JA; García Sánchez E; Fresnadillo Martínez MJ
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():2-7. PubMed ID: 9410064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
    Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
    Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
    Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM; Yang YJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009).
    Mayne D; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2012 Oct; 74(2):151-7. PubMed ID: 22770774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
    Bujdáková H; Kallová J; Lausová A; Kettner M
    Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W; Pitkin DH; Nadler H
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [In vitro antibacterial activity and beta-lactamase stability of meropenem].
    Poiată A; Tuchiluş C; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):589-94. PubMed ID: 14756067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.